The FDA approved a targeted therapy, Vyloy, in combination with chemotherapy for gastric cancer at the gastroesophageal junction, marking a significant milestone in cancer treatment.
The article delves into the crisis facing 25,000 U.S. patients who rely on parenteral nutrition due to their inability to digest food, exacerbated by CVS's exit from the business and compounded by supply shortages.
A study reveals that opioids not only slow gastrointestinal transit but also disrupt intestinal permeability, potentially leading to bacterial translocation and systemic inflammation, with peripherally acting μ-opioid receptor antagonists showing promise in mitigating these effects.
Research highlights the complex evolution of pancreatic neuroendocrine tumors, demonstrating how therapy-induced mutations can lead to high-grade disease progression.
Conexiant
Daily News
Stay up to date with the latest clinical headlines.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A nationwide study of over 10 million privately insured individuals found that colorectal cancer screening uptake among 45- to 49-year-olds tripled after the 2021 USPSTF recommendation, with 13.9% receiving screening before age 50.
A large study finds Helicobacter pylori (H. pylori) screening alongside colorectal cancer screening does not significantly reduce gastric cancer rates over five years, challenging assumptions about population-wide screening effectiveness.
Eighty FCCs had properties that warrant further investigation for potential health concerns, such as carcinogenic, mutagenic, and reproductive toxicity.